Khan Mohd Shahnawaz, Al-Twaijry Nojood, Alotaibi Fai N, Alenad Amal M, Alokail Majed S, Arshad Mohammed, Al Kheraif Abdul Aziz, Elrobh Mohamed, Shaik Gouse M
Department of Biochemistry, College of Science, King Saud University, 11451, Riyadh, Saudi Arabia.
College of Applied Medical Science, King Saud University, Riyadh, Saudi Arabia.
J Fluoresc. 2024 Jun 24. doi: 10.1007/s10895-024-03792-9.
Free radicals, products of oxidative processes, induce cellular damage linked to diseases like Parkinson's and diabetes due to increased reactive oxygen species (ROS) levels. Catalase, crucial for scavenging ROS, emerges as a therapeutic agent against ailments including atherosclerosis and tumor progression. Its primary function involves breaking down hydrogen peroxide into water and oxygen. Research on catalase-drug interactions reveals structural changes under specific conditions, affecting its activity and cellular antioxidant balance, highlighting its pivotal role in defending against oxidative stress-related diseases. Hence, targeting catalase is considered an effective strategy for controlling ROS-induced cellular damage. This study investigates the interaction between bovine liver catalase and glipizide using spectroscopic and computational methods. It also explores glipizide's effect on catalase activity. More than 20% inhibition of catalase enzymatic activity was recorded in the presence of 50 µM glipizide. To investigate the inhibition of catalase activity by glipizide, we performed a series of binding studies. Glipizide was found to form a complex with catalase with moderate affinity and binding constant in the range of 3.822 to 5.063 × 10 M. The binding was spontaneous and entropically favourable. The α-helical content of catalase increased from 24.04 to 29.53% upon glipizide complexation. Glipizide binding does not alter the local environment surrounding the tyrosine residues while a notable decrease in polarity around the tryptophan residues of catalase was recorded. Glipizide interacted with numerous active site residues of catalase including His361, Tyr357, Ala332, Asn147, Arg71, and Thr360. Molecular simulations revealed that the catalase-glipizide complex remained relatively stable in an aqueous environment. The binding of glipizide had a negligible effect on the secondary structure of catalase, and hydrogen bonds persisted consistently throughout the trajectory. These results could aid in the development of glipizide as a potent catalase inhibitor, potentially reducing the impact of reactive oxygen species (ROS) in the human body.
自由基作为氧化过程的产物,由于活性氧(ROS)水平升高,会引发与帕金森病和糖尿病等疾病相关的细胞损伤。过氧化氢酶对于清除ROS至关重要,它作为一种治疗剂,可对抗包括动脉粥样硬化和肿瘤进展在内的疾病。其主要功能是将过氧化氢分解为水和氧气。对过氧化氢酶 - 药物相互作用的研究揭示了在特定条件下的结构变化,这会影响其活性和细胞抗氧化平衡,凸显了其在抵御氧化应激相关疾病中的关键作用。因此,靶向过氧化氢酶被认为是控制ROS诱导的细胞损伤的有效策略。本研究使用光谱学和计算方法研究了牛肝过氧化氢酶与格列吡嗪之间的相互作用。它还探讨了格列吡嗪对过氧化氢酶活性的影响。在存在50μM格列吡嗪的情况下,记录到过氧化氢酶酶活性受到超过20%的抑制。为了研究格列吡嗪对过氧化氢酶活性的抑制作用,我们进行了一系列结合研究。发现格列吡嗪与过氧化氢酶形成具有中等亲和力的复合物,结合常数在3.822至5.063×10 M范围内。这种结合是自发的且在熵方面是有利的。与格列吡嗪络合后,过氧化氢酶的α - 螺旋含量从24.04%增加到29.53%。格列吡嗪的结合不会改变酪氨酸残基周围的局部环境,而记录到过氧化氢酶色氨酸残基周围的极性显著降低。格列吡嗪与过氧化氢酶的许多活性位点残基相互作用,包括His361、Tyr357、Ala332、Asn147、Arg71和Thr360。分子模拟表明,过氧化氢酶 - 格列吡嗪复合物在水性环境中保持相对稳定。格列吡嗪的结合对过氧化氢酶的二级结构影响可忽略不计,并且氢键在整个轨迹中持续存在。这些结果有助于将格列吡嗪开发为一种有效的过氧化氢酶抑制剂,可能会降低人体中活性氧(ROS)的影响。